New Adrulipase Formulation Slated for Proof-of-concept Phase 2 Trial

Retrieved on: 2022-09-09 19:07:30

Tags for this article:

Click the tags to see associated articles and topics

New Adrulipase Formulation Slated for Proof-of-concept Phase 2 Trial. View article details on hiswai:

Excerpt

First Wave BioPharma has developed a new formulation of adrulipase, a yeast-derived enzyme to treat exocrine pancreatic insufficiency in CF.

Article found on: cysticfibrosisnewstoday.com